| Amanda Mohabir, MD | |
|
4500 S Lancaster Rd, Dallas, TX 75216-7167 | |
| (214) 742-8387 | |
| Not Available |
| Full Name | Amanda Mohabir |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 4500 S Lancaster Rd, Dallas, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326147356 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | L8440 (Texas) | Primary |
| Entity Name | The Doctors Office Of Manalapan Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356604409 PECOS PAC ID: 8022268069 Enrollment ID: O20121029000009 |
News Archive
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
About 26% percent of the American workforce, including health-care workers and sanitation staff, need to work night shifts. Earlier research has shown that regular night shifts may disrupt the circadian rhythm, raising the risk of heart disease, obesity, ulcers and even depression.
Daylight Solutions, Inc., a leading manufacturer of molecular detection and imaging solutions in the mid-infrared, today announced the launch of the world's first commercially available laser-based infrared microscopy platform.
› Verified 4 days ago
| Entity Name | Central Jersey Urgent Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316285091 PECOS PAC ID: 7618114323 Enrollment ID: O20130516000050 |
News Archive
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
About 26% percent of the American workforce, including health-care workers and sanitation staff, need to work night shifts. Earlier research has shown that regular night shifts may disrupt the circadian rhythm, raising the risk of heart disease, obesity, ulcers and even depression.
Daylight Solutions, Inc., a leading manufacturer of molecular detection and imaging solutions in the mid-infrared, today announced the launch of the world's first commercially available laser-based infrared microscopy platform.
› Verified 4 days ago
| Entity Name | Doctors Office Of Brick |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184067944 PECOS PAC ID: 1254575061 Enrollment ID: O20130918000138 |
News Archive
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
About 26% percent of the American workforce, including health-care workers and sanitation staff, need to work night shifts. Earlier research has shown that regular night shifts may disrupt the circadian rhythm, raising the risk of heart disease, obesity, ulcers and even depression.
Daylight Solutions, Inc., a leading manufacturer of molecular detection and imaging solutions in the mid-infrared, today announced the launch of the world's first commercially available laser-based infrared microscopy platform.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Mohabir, MD 445 White Horse Ave, Hamilton, NJ 08610-1408 Ph: (609) 585-1122 | Amanda Mohabir, MD 4500 S Lancaster Rd, Dallas, TX 75216-7167 Ph: (214) 742-8387 |
News Archive
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
About 26% percent of the American workforce, including health-care workers and sanitation staff, need to work night shifts. Earlier research has shown that regular night shifts may disrupt the circadian rhythm, raising the risk of heart disease, obesity, ulcers and even depression.
Daylight Solutions, Inc., a leading manufacturer of molecular detection and imaging solutions in the mid-infrared, today announced the launch of the world's first commercially available laser-based infrared microscopy platform.
› Verified 4 days ago
Dr. Juan F Quiroz, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4811a Columbia Ave, Dallas, TX 75226 Phone: 214-823-5590 Fax: 214-823-6638 | |
Dr. Michelle Dobbs, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 6333 E Mockingbird Ln, Suite 126, Dallas, TX 75214 Phone: 214-826-6005 | |
Howard J Huntzinger, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9250 Amberton Pkwy, Dallas, TX 75243 Phone: 682-236-3656 | |
Robert J Dimeff, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8081 Walnut Hill Ln, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 | |
Pardeep K Shori, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7012 La Vista Dr, Dallas, TX 75214 Phone: 817-564-5761 | |
Mary Elizabeth Wilcox Smith, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2921 Fairmount St, Dallas, TX 75201 Phone: 214-742-9310 | |
Elizabeth Chapek, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 6760 Abrams Rd, Suite 203, Dallas, TX 75231 Phone: 214-341-8742 |